» Articles » PMID: 24363091

The Proteasome Function Reporter GFPu Accumulates in Young Brains of the APPswe/PS1dE9 Alzheimer's Disease Mouse Model

Overview
Publisher Springer
Date 2013 Dec 24
PMID 24363091
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD), the most common cause of dementia, is neuropathologically characterized by accumulation of insoluble fibrous inclusions in the brain in the form of intracellular neurofibrillary tangles and extracellular senile plaques. Perturbation of the ubiquitin-proteasome system (UPS) has long been considered an attractive hypothesis to explain the pathogenesis of AD. However, studies on UPS functionality with various methods and AD models have achieved non-conclusive results. To get further insight into UPS functionality in AD, we have crossed a well-documented APPswe/PS1dE9 AD mouse model with a UPS functionality reporter, GFPu, mouse expressing green fluorescence protein (GFP) fused to a constitutive degradation signal (CL-1) that facilitates its rapid turnover in conditions of a normal UPS. Our western blot results indicate that GFPu reporter protein was accumulated in the cortex and hippocampus, but not striatum in the APPswe/PS1dE9 AD mouse model at 4 weeks of age, which is confirmed by fluorescence microscopy and elevated levels of p53, an endogenous UPS substrate. In accordance with this, the levels of ubiquitinated proteins were elevated in the AD mouse model. These results suggest that UPS is either impaired or functionally insufficient in specific brain regions in the APPswe/PS1dE9 AD mouse model at a very young age, long before senile plaque formation and the onset of memory loss. These observations may shed new light on the pathogenesis of AD.

Citing Articles

Raw polysaccharide counteracts Alzheimer's disease in a transgenic mouse model by activating the ubiquitin-proteosome system.

Wang S, Dong K, Zhang J, Chen C, Shuai H, Yu X Nutr Res Pract. 2023; 17(6):1128-1142.

PMID: 38053824 PMC: 10694425. DOI: 10.4162/nrp.2023.17.6.1128.


Effects of Phenylethanoid Glycosides Extracted from on the Learning and Memory of the APP/PSI Transgenic Mice with Alzheimer's Disease.

Yang J, Ju B, Hu J Biomed Res Int. 2021; 2021:1291549.

PMID: 33532488 PMC: 7834784. DOI: 10.1155/2021/1291549.


Pharmacological intervention in a transgenic mouse model improves Alzheimer's-associated pathological phenotype: Involvement of proteasome activation.

Mladenovic Djordjevic A, Kapetanou M, Loncarevic-Vasiljkovic N, Todorovic S, Athanasopoulou S, Jovic M Free Radic Biol Med. 2020; 162:88-103.

PMID: 33279620 PMC: 7889698. DOI: 10.1016/j.freeradbiomed.2020.11.038.


Priming the Proteasome to Protect against Proteotoxicity.

Wang X, Wang H Trends Mol Med. 2020; 26(7):639-648.

PMID: 32589934 PMC: 7321925. DOI: 10.1016/j.molmed.2020.02.007.


The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Tundo G, Sbardella D, Santoro A, Coletta A, Oddone F, Grasso G Pharmacol Ther. 2020; 213:107579.

PMID: 32442437 PMC: 7236745. DOI: 10.1016/j.pharmthera.2020.107579.


References
1.
Layfield R, Lowe J, Bedford L . The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem. 2005; 41:157-71. DOI: 10.1042/EB0410157. View

2.
Upadhya S, Hegde A . Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem. 2007; 8 Suppl 1:S12. PMC: 2106363. DOI: 10.1186/1471-2091-8-S1-S12. View

3.
Kumarapeli A, Horak K, Glasford J, Li J, Chen Q, Liu J . A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J. 2005; 19(14):2051-3. DOI: 10.1096/fj.05-3973fje. View

4.
Crivello N, Rosenberg I, Shukitt-Hale B, Bielinski D, Dallal G, Joseph J . Aging modifies brain region-specific vulnerability to experimental oxidative stress induced by low dose hydrogen peroxide. Age (Dordr). 2009; 29(4):191-203. PMC: 2267029. DOI: 10.1007/s11357-007-9039-7. View

5.
Orre M, Kamphuis W, Dooves S, Kooijman L, Chan E, Kirk C . Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain. 2013; 136(Pt 5):1415-31. DOI: 10.1093/brain/awt083. View